Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2006

01-01-2006

Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies

Authors: Michelle D. Martin, Susan G. Hilsenbeck, Syed K. Mohsin, Torsten A. Hopp, Gary M. Clark, C. Kent Osborne, D. Craig Allred, Peter O’Connell

Published in: Breast Cancer Research and Treatment | Issue 1/2006

Login to get access
Metadata
Title
Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies
Authors
Michelle D. Martin
Susan G. Hilsenbeck
Syed K. Mohsin
Torsten A. Hopp
Gary M. Clark
C. Kent Osborne
D. Craig Allred
Peter O’Connell
Publication date
01-01-2006
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-9016-8

Other articles of this Issue 1/2006

Breast Cancer Research and Treatment 1/2006 Go to the issue

Epidemiology

Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype–phenotype correlations

OriginalPaper

Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation

Clinical trial

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

OriginalPaper

Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer

Letter to the editor

Can the apparent conflicting roles of PKC δ on cell proliferation and survival be reconciled?

Clinical trial

Factors predicting the sentinel and non-sentinel lymph node metastases in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits